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Abstract
Background Yes Associated Protein (YAP) has been impli-
cated in the control of organ size by regulating cell prolifera-
tion and survival. YAP is a transcriptional coactivator that
controls cellular responses through interaction with TEAD
transcription factors in the nucleus, while its transcriptional
functions are inhibited by phosphorylation-dependent translo-
cation to the cytosol. YAP overexpression has been associated
with different types of cancer, such as lung, skin, prostate,
ovary and liver cancer. Recently, YAP was linked to E-
cadherin-dependent regulation of contact inhibition in breast
cancer cells.
Results In this study we examined YAP protein expression
and cellular localization in 237 cases of human invasive breast
cancer by immunohistochemistry and related its expression to
clinicopathological features and E-cadherin expression. We
observed that invasive lobular carcinoma is characterized by
higher expression levels of both nuclear and cytosolic YAP
(p<0.001). Nuclear YAP expression did not associate with
other variables such as lymph node involvement, tumor grade,
tumor size, mitotic activity or the molecular sub-types of
invasive breast cancer. We observed that high nuclear and
cytosolic YAP expression are associated with the E-cadherin
deficient breast cancer subtype ILC (p<0.001) and cell lines
derived from human breast cancers and conditional mouse
models of human lobular breast cancer.
Conclusions Since our data indicate that nuclear YAP locali-
zation is more common in breast cancers lacking functional
adherens junctions, it suggests that YAP-mediated transcrip-
tion may be involved in the development and progression of
invasive lobular breast cancer.
Keywords Adhesion . Breast cancer . Yap (Hippo)
signaling . Invasive Lobular Carcinoma
1 Introduction
Breast cancer prognosis strongly depends on the capacity of
tumor cells to invade and colonize foreign tissues, a process
that has been linked to the functional loss of cell-cell adhesion.
In breast cancer, expression of the tumor suppressor E-cadherin
- a key component of the adherens junction (AJ) - is widely
used to facilitate differential diagnosis between invasive ductal
(IDC) and invasive lobular breast cancer (ILC) [1, 2]. While
mutational inactivation of E-cadherin is a causal event in the
formation of ILC [4–6], IDC often expresses E-cadherin [3–5].
In IDC, (epigenetic) inactivation of the AJ occurs at later
stages, which is thought to induce an epithelial to mesenchy-
mal transition (EMT) and subsequent tumor progression [6, 7].
Despite this, little is known regarding the prometastatic down-
stream molecular processes that are aberrantly regulated upon
loss of E-cadherin-mediated cell-cell adhesion.
Recently, a transcriptional coactivator named Yorkie was
identified in Drosophila as an important regulator of prolifer-
ation and apoptosis [8, 9]. Yorkie is a downstream component
of the Hippo pathway, consisting of the kinase complexes
Hippo-Salvador and Warts-Mats [9–11]. The kinases of the
Hippo pathway inhibit Yorkie activity through phosphoryla-
tion (Serine 168 inDrosophila) [12]. Subsequent dephosphor-
ylation of Yorkie induces translocation to the nucleus, where it
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activates transcription to regulate organ size [13, 14]. Yorkie
has two homologues in humans, called YAP (Yes Associated
Protein) and TAZ (transcriptional coactivator with PDZ-
binding motif, also known as WWTR1) [15]. Two YAP splice
variants can be identified, containing either one or two dual
WW domains (YAP1 and YAP2, respectively)[16]. Although
Hippo pathway components are conserved in mammals, regu-
lation of YAP signaling seems to be tissue-specific. In mouse
liver, Mst1/2 (Hippo in Drosophila) inhibits activation of the
YAP orthologue Yorkie [12]. However, in mammalian skin
neither Mst1/2 nor Lats1/2 (Hippo and Warts respectively in
Drosophila) influence YAP-mediated signaling [13]. Instead,
the AJ member αE-catenin appears to regulate YAP activity. In
this setting, αE-catenin binds to phosphorylated YAP (Serine
127 in humans) via the 14-3-3 adaptor protein, which prevents
YAP binding to and subsequent dephosphorylation by the
phosphatase PP2A [13]. Upon disruption of the AJ complex,
YAP can be activated by PP2A and subsequently translocate
into the nucleus where it drives transcriptional activation [13].
Interestingly, little is known about the regulation mecha-
nism of YAP in breast tissue. Although it is clear that YAP
may be differently regulated in breast tissue compared to its
orthologue Yorkie, it is still under debate how YAP is phos-
phorylated and whether this affects YAP activity [17–22]. In
breast cancer cell lines, E-cadherin regulates contact-inhibited
proliferation through regulation of YAP activation [18, 23].
Here, cell proliferation is inhibited by cell density via α-
catenin and αE-catenin-dependent phosphorylation of YAP
at serine residue 127 in humans (S112 in mouse) and subse-
quent translocation of YAP into the cytosol [18, 23].
Moreover, recent data indicate that YAPmay also be regulated
by the actin and microtubule cytoskeleton [17, 20, 22], al-
though the exact mechanism is largely unknown.
Several observations suggest an oncogenic role for YAP
signaling in breast cancer. First, the YAP locus was found
amplified in a mammary tumor that developed in aMMTVcre;
Brca1Δ11/co; Trp53+/− conditional mouse model [24]. Second,
cytosolic YAP was found overexpressed in 31 % of human
luminal ductal breast cancers [25]. Also, YAP overexpression
resulted in transforming abilities in E-cadherin positive human
breast cancer cell lines [22, 24–26]. Finally, YAP/TAZ-
mediated transcriptional activity was linked to the mainte-
nance of a cancer stem cell phenotype in breast cancer [27].
In contrast, loss of YAP expression correlated with estrogen
receptorα (ERα) and progesterone receptor (PR) negativity in
breast cancer [28], suggesting that YAPmay also function as a
tumor suppressor. Furthermore, loss of heterozygosity (LOH)
of the YAP gene locus (located at 11q22.2), was frequently
found in sporadic breast cancer [29–33]. Finally, loss of YAP
expression was implicated in the induction of anoikis resis-
tance and increased invasiveness [34].
Overall, the current literature indicates a role for YAP in
breast cancer and suggests that the AJ and its downstream
effectors may regulate YAP. Here, we analyzed 237 invasive
human breast cancer samples by relating expression and lo-
calization of YAP to clinicopathological features and E-
cadherin expression. Our data indicate that high nuclear and
cytosolic YAP expression are associated with the E-cadherin
deficient breast cancer subtype ILC. Furthermore, using hu-
man breast cancer cell lines and conditional mouse models of
human ILC, we substantiate that nuclear localization of YAP
is linked to loss of E-cadherin expression. Our data thus
indicate that nuclear YAP is a feature of invasive breast
cancers lacking a functional AJ, which suggests a role for
YAP signaling in ILC.
2 Materials and methods
2.1 Patients
The study population was derived from the archives of the
Departments of Pathology of the University Medical Center
Utrecht, Utrecht, and the Radboud University Nijmegen
Medical Centre, Nijmegen, The Netherlands. These com-
prised 237 cases of invasive breast cancer (operated between
2003 and 2007). Histological grade was assessed according to
the Nottingham scheme [35], and mitotic activity index (MAI)
was assessed as before [36]. The clinicopathologic character-
istics are shown in Table 1.
Table 1 Clinicopathological characteristics of the 237 invasive breast
cancer patients studied for the expression of YAP
Feature Grouping N or value %
Age (years) Mean 60
Range 28 to 88
Histologic type IDC 187 78.9
ILC 50 21.1
Tumor size (cm) ≤2 108 45.6
>2 and ≤5 98 41.4
>5 30 12.7
Not available 1 0.4
Histologic grade 1 36 15.2
2 76 32.1
3 125 52.7
MAI ≤ 12 103 43.5
≥ 13 134 56.5
Lymph node status Negative* 98 41.4
Positive** 125 52.7
Not available 14 5.9
# per 2 mm2
*negative=N0 or N0(i+)
**positive=≥N1mi (according to TNM 7th edition, 2010)
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From representative donor paraffin blocks of the primary
tumors, tissue microarrays were constructed by transferring
tissue cylinders of 0.6 mm (3 cylinders per tumor) from the
tumor area, determined by a pathologist based on haematoxylin-
eosin stained slides, using a tissue arrayer (Beecher Instruments,
Sun Prairie, WI, USA) as described before [37]. Normal breast
tissue was obtained from patients that underwent mammoplasty,
and was thus tumor-free. The use of anonymous or coded left
over material for scientific purposes is part of the standard
treatment contract with patients in The Netherlands [38], and
no ethical approval is required according to Dutch legislation (as
is stated by the Dutch committee for research on patient material
‘Centrale Commissie Mensgebonden Onderzoek’).
2.2 Immunohistochemistry
Immunohistochemistry was carried out on 4 μm thick sections.
After deparaffination and rehydration, endogenous peroxidase
activity was blocked for 15 min in a 46 mM citric acid-100 mM
sodium phosphate buffer solution (pH5.8) containing 0.3 %
hydrogen peroxide. After antigen retrieval, i.e. boiling for
20 min in 10 mM citrate pH6.0 (PR, YAP), Tris/EDTA pH9.0
(E-cadherin, ERα, HER2), a cooling period of 30 min preceded
the primary antibody incubation. Primary antibodies against E-
cadherin (clone 4A2C7, Zymed, Invitrogen, Breda, The
Netherlands) 1:200; ERα (clone ID5, DAKO, Glostrup
Denmark) 1:80; PR (clone PgR636, DAKO) 1:25; HER2
(SP3, Neomarkers, Duiven, The Netherlands) 1:100 were dilut-
ed in PBS containing 2%BSA and incubated for 1 h at room
temperature. Primary antibodies against YAP (1:50, cat 4912,
Cell Signaling), (YAP-IHC) were incubated over night at 4 °C.
The signal was amplified using Powervision poly-HRP anti-
mouse, -rabbit, -rat (DPVO-HRP, Immunologic, Duiven, The
Netherlands), followed by counterstaining with haematoxylin,
dehydration in alcohol, and mounting.
2.3 Scoring of immunohistochemistry
All scoring was done blinded to patient characteristics and
results of other stainings by two individual observers. E-
cadherin expression was scored using the DAKO/HER2 scor-
ing system for membranous staining. Membranous scores 1+,
2+, and 3+ were considered positive, except for HER2 where
only a score of 3+ was considered positive. Percentages of
cells with nuclear YAP staining were estimated, and samples
with more than 20 % positive tumor nuclei were considered
positive. Intensity of cytosolic YAP expression was semi-
quantitatively scored as 0, 1, 2 or 3, regarding scores 2 and 3
as high. Based on ER, PR, and HER2 immunohistochemistry,
tumors were classified as luminal (ERα and/or PR positive),
HER2-driven (ER-, PR-, HER2+), or basal-like/triple nega-
tive (ER-, PR-, HER2- with or without EGFR expression), the
immunohistochemical surrogate [39] of the original Sorlie/
Perou classification [40].
2.4 Statistics
Statistical analysis was performed using SPSS Statistics version
18.0 (SPSS Inc., Chicago, IL, USA). Associations between
categorical variables were examined using the Pearson’s Chi-
square test. P-values <0.05 were considered to be statistically
significant.
2.5 Cell culture
Origin and culture of the mouse cell lines Trp53Δ/Δ-4, Trp53Δ/Δ-
7, mILC-1 andmILC-3were described before [41]. ILC cell line
IPH-926 was a kind gift from Dr. M. Christgen (Hannover
Medical School, Hannover, Germany) and cultured as described
[42]. Human breast cancer cell lineMCF10Awas obtained from
American Type Culture Collection (ATCC), while T47D and
SKBR-3 were a kind gift from Dr. J. Martens (ErasmusMedical
Center, Rotterdam, The Netherlands) and originate from the
American Type Culture Collection (ATCC). These cell lines
were cultured in DMEM-F12 (Sigma), and validated by Short
TandemRepeat (STR) profiling. All media contained 10% fetal
calf serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin,
and all cell lines were maintained at 37 °C in a 5 % CO2
humidified atmosphere.
2.5.1 Western blotting
Samples were lysed in sample buffer containing 50 mM Tris-
HCl (pH 6.8), 0.5 % β-mercaptoethanol, 2 % SDS, 0.005 %
bromophenolblue, and 10 % glycerol (all Sigma-Aldrich).
Samples were heated for 10 min at 100 °C and proteins were
separated using standard PAGE protocols and blotting as
described previously [43].
2.5.2 Nuclear fractionation
Cells were grown to confluence, washed with PBS containing
Mg2+ and Ca2+ (PBS+), scraped from the plate and suspended
in buffer A (10 mM HEPES pH 7.9, 1.5 mMMgCL2, 10 mM
KCl and freshly added 1 mM DTT, 0.5 mM PMSF, 5ug/ml
leupeptin, 5ug/ml aprotinin). Cells were centrifuged at 400 g at
4 °C for 5 min, resuspended in 1 ml PBS+, and centrifuged.
Cells were resuspended in buffer A, centrifuged and
resuspended again in buffer A. Cells were incubated for
10 min on ice, centrifuged, resuspended in buffer A and me-
chanically lysed with 50–75 strokes in a glass 2 mL-douncer.
Cell lysates were centrifuged for 10 min at 500 g at 4 °C. Cell
pellets (nuclear fraction) were separated from the supernatant
(cytosolic fraction). Both fractions were submitted to another
round of washing and centrifugation (10 min, 500 g at 4 °C)
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and used for western blotting. Rabbit anti-TAF5, [44], was used
as a nuclear marker, and goat anti-AKT (1:1000; cat sc-1618,
Santa Cruz Biotechnology) was used as a cytosolic marker. The
primary antibody against YAPwasmouse anti-YAP (1:200; cat
sz101199, Santa Cruz), (YAP-IF).
2.5.3 Constructs, viral production and transduction
Cos-7 cells were transfected using X-tremeGene9 (cat
06365809001, Roche), and lentiviral particles were produced
using third-generation packaging constructs as described [41].
For knockdown of YAP we used pLKO1-shYAP1 (cat 27368
addgene). Supernatant containing viral particles was harvested
48 h after transfection, passed through a 45-μm filter, and
concentrated 15- to 20-fold by centrifugation (175,000 g;
150 min). Cells were transduced overnight in the presence of
4 μg/ml polybrene (Sigma-Aldrich).
2.6 Immunofluorescence
Cells were cultured on glass coverslips and fixed in 1 %
paraformaldehyde in PBS for 10 min on ice, permeabilized
using 0.3 % Triton-X100/PBS and subsequently blocked
with 4 % BSA in PBS (Roche, Woerden, The Netherlands).
Formalin fixed and paraffin embedded (FFPE) tissue slides
were treated as described for immunohistochemistry stain-
ing. Blocking was done with 4 % BSA in PBS after antigen
retrieval. FFPE slides were incubated with rabbit anti-YAP
(1:50; cat 4912, Cell Signaling), (YAP-IHC), at 4 °C over-
night. The mouse anti-p63 antibody (1:400; MS-115-P,
Neomarkers) was incubated for 1 h at room temperature.
Directly conjugated antibodies against E-cadherin (1:150,
612130 BD and 560062 BD Biosciences) were incubated
for 1–3 h at room temperature. All antibodies were diluted
in 4 % BSA/PBS. Secondary antibodies were incubated in
4 % BSA/PBS for 1 h (goat anti-rabbit Alexa-555, cat
A21428, goat anti-mouse highly cross-adsorbed Alexa-
488 and Alexa-568, cat A11029 and A11031, and goat
anti-rabbit highly cross-adsorbed Alexa-488 and Alexa-
568, cat A11036 and A11034, all from Invitrogen). Cell
lines grown on glass coverslips were incubated with mouse
anti-YAP (1:50; cat sz101199, Santa Cruz), (YAP-IF), in
4 % BSA at 4 °C over night. Subsequently, cells were
incubated in 4 % BSA with goat anti-mouse Alexa-555
(1:600; cat A21422, Invitrogen) for 1 h. DNA was stained
with DAPI (1:1000; cat D1306, Invitrogen) for 5 min at
room temperature. Cover slips were mounted using
Vectashield (Vector Laboratories, Burlingame, USA) and
analyzed either by a Zeiss LSM 510 Meta confocal laser
microscope using a 63×1.4 objective or by using the Zeiss
LSM 700 confocal laser microscope using the 63X 1.4
objective.
3 Results
3.1 YAP expression in human and mouse normal breast tissue
In normal human breast tissue, we found YAP to be predom-
inantly expressed in the outer layer of the ducts, the
myoepithelium (Fig. 1a and Online Resource Fig. 1). While
YAP was expressed at low levels in the cytosol, we detected
prominent nuclear YAP staining using immunofluorescence
in this cell type (Fig. 1a, arrowheads and Online Resource
Fig. 1). In contrast, E-cadherin-expressing luminal cells
showed low YAP expression that was mainly localized to
the apical snouts (Fig. 1a, arrow and and Online Resource
Fig. 1). Next, we assessed YAP expression and localization in
mouse mammary epithelium. As in the human tissue, mouse
myoepithelial cells showed a stronger nuclear YAP localiza-
tion pattern (arrowheads), whereas luminal mammary epithe-
lial cells mostly expressed cytoplasmic YAP (Fig. 1b).
Specificity of the YAP-IF antibody used was confirmed by
performing shRNA-mediated knock-down (Online Resource
Fig. 2, middle panel).
3.2 Nuclear YAP localization in invasive lobular carcinoma
To investigate the expression pattern of YAP in invasive breast
cancer, we stained a tissue micro array (TMA) containing 237
invasive breast cancer samples using immunohistochemistry
(IHC). The clinicopathological characteristics of these tumors
are shown in Table 1. Because YAP functions as a mediator of
transcriptional activation, we based our score on an estimation
of the percentage of YAP positive nuclei. Representative
pictures of nuclear YAP staining are shown in Figure 2A.
Moreover, since YAP shuttles between the nucleus and the
cytoplasm, we scored the intensity of cytoplasmic YAP as
well (Fig 2b). Since a different antibody was used for IHC
(YAP-IHC), we also confirmed specificity for this antibody by
using a YAP knock-down approach (Online Resource Fig. 2,
top panel). Analysis of the YAP expression patters showed
that both high cytoplasmic levels and nuclear YAP localiza-
tion correlated with the histological type of breast cancer
invasive lobular carcinoma (ILC) (p=0.002 and p<0.001,
respectively; Table 2 and 3). We used 20 % as cut-off value
for positive nuclear YAP staining, although 5 % and 10% cut-
off were also statistically significant (p<0.001 for both 5 %
and 10 %). Neither cytosolic nor nuclear YAP expression
correlated with histological grade, mitotic activity or lymph
node status (Tables 2 and 3).We also analyzed the relationship
between YAP expression and tumor size. Because ILC tumors
were significantly larger compared to the IDC tumors, we
corrected for this and found that nuclear YAP expression
was not correlated with tumor size (odd ratio 1.451, 95 %
confidence interval of 0.790 to 2.667), while high nuclear
YAP localization remained significantly correlated with ILC
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a E-cadherin MergeYAP
b E-cadherin MergeYAP
Fig. 1 YAP expression in human and mouse normal breast tissue. aYAP
expression in normal human breast tissue. Shown are immunofluores-
cence for YAP (middle panel, red) and E-cadherin (left panel, green).
Nuclei were visualized using DAPI. Right panel depicts the merged
image. Luminal epithelial cells form clear AJ and are characterized by
low cytosolic YAP expression. Note the predominant nuclear YAP
localization in myoepithelial cells (arrowheads) and expression of YAP
in apical snouts (arrow). Size bar=5 μm. b. YAP expression in mouse
mammary glands. Shown are immunofluorescence for YAP (middle
panel, red) and E-cadherin (left panel, green). Arrowheads depict nuclear
YAP expression in mouse myoepithelial cells. Nuclei were visualized
using DAPI. Right panel depicts the merged image. Size bar=5 μm
a 0%
Nuclear YAP
>20%
b
Cytosolic YAP
Low High
Fig. 2 YAP expression in human
invasive breast cancer. a Nuclear
YAP expression patterns. Shown
are representative examples of
immunohistochemistry of YAP
(IHC). The percentage of nuclei
that showed YAP expression was
determined and scored as 0% (left
panel) or more than 20 % (right
panel). Arrows denote nuclear
staining. b Cytosolic intensities of
YAP expression. Shown are
representative examples of
immunohistochemistry of YAP
(IHC). Cytosolic YAP expression
was scored as either low YAP (left
panel) or high YAP (right panel).
The sample shown in
the right panel was also
scored <20 % (15–20 %) for
nuclear YAP localization. Size
bar=25 μm
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tumors (odds ratio 8.829, 95 % confidence interval of 4.208 to
18.523) (Table 3). In contrast to previously published data
[28], we did not find a correlation between nuclear or cyto-
solic YAP localization and hormone receptor status, HER2
expression or molecular breast cancer subtypes (Online
Resource Table 1 and Table 2). In conclusion, increased
cytosolic YAP expression and nuclear YAP localization are
associated with ILC.
3.3 High YAP expression is correlated with human and mouse
ILC
Since E-cadherin has been implicated in the regulation of YAP
activity in human breast cell lines [17, 18, 23], we analyzed
whether E-cadherin expression was correlated with YAP ex-
pression in our invasive breast cancer samples. Indeed, we
found that high cytoplasmic as well as high nuclear YAP
expression inversely correlated with E-cadherin expression
(p=0.024 and p<0.001, respectively, Table 4, Table 5 and
Fig. 3). We substantiated the correlation between E-cadherin
loss and nuclear YAP localization in ILC by analyzing YAP
expression in a set of E-cadherin expressing and E-cadherin
mutant (lobular) breast cancer cell lines. In agreement with the
findings in our invasive breast cancer cohort we observed that
the E-cadherin positive cell lines T47D and MCF10A showed
cytosolic YAP staining (Fig 4a), whereas the E-cadherin mu-
tant cell lines SKBR-3 and lobular breast cancer cell line IPH- 926 [42, 45], showed predominately nuclear YAP localization
(Fig 4c). Next, we used tumor cell lines generated from
mammary tumors that developed in conditional mousemodels
based on tissue-specific and conditional inactivation of E-
cadherin and/or p53. In these mice, inactivation of E-
cadherin is causal to the formation of invasive and metastatic
tumors that mimic human ILC [4, 5]. Using immunofluores-
cence we compared YAP localization in Trp53Δ/Δ (E-cadherin
positive, p53 negative) and mouse ILC (mILC) (E-cadherin
and p53 negative) cell lines. Similar to their human counter-
parts, mILC cells showed an increase in nuclear YAP locali-
zation. Furthermore, while both mILC and Trp53Δ/Δ cells
showed cytosolic YAP, YAP expression in Trp53Δ/Δ cell lines
was mainly cytoplasmic (Fig 4b and d). In order to corroborate
our finding that nuclear YAP expression is a hallmark of E-
cadherin mutant breast cancer, we performed nuclear fraction-
ation of human and mouse cell lines, which were compared
using western blot analyses. Indeed, using TAF5 as a nuclear
marker we observed that in both species E-cadherin negative
cell lines showed an enrichment of nuclear YAP when com-
pared to their E-cadherin expressing counterparts (Online
Resource Fig. 3). In conclusion, our data indicate that YAP
localization is inversely correlated with E-cadherin expres-
sion, since nuclear YAP is a characteristic of E-cadherin
negative ILC from mice and man.
Table 2 Correlations of cytosolic YAP with clinicopathological features
in invasive breast cancer
Feature N Cytosolic YAP expression
Negative N (%)
Positive
N (%)
p-value
Histologic type
IDC 187 126 (67.4) 61 (32.6) 0.002
ILC 49 21 (42.9) 28 (57.1)
Histologic grade
1 36 25 (69.4) 11 (30.6) 0.626
2 76 46 (60.5) 30 (39.5)
3 124 76 (61.3) 48 (38.7)
Tumor size (cm)
≤2 108 67 (62.0) 41 (38.0) 0.240
>2 and ≤5 97 65 (67.0) 32 (33.0)
>5 30 15 (50.0) 15 (50.0)
MAI (per 2 mm2)
≤12 103 64 (62.1) 39 (37.9) 0.966
≥13 133 83 (62.4) 50 (37.6)
Lymph node status
Negative 97 57 (58.8) 40 (41.2) 0.426
Positive 125 80 (64.0) 45 (36.0)
Table 3 Correlations of nuclear YAPwith clinicopathological features in
invasive breast cancer
Feature N Nuclear YAP expression
Low (<20 %)
N (%)
High (≥20 %)
N (%)
p-value
Histologic type
IDC 187 140 (74.9) 47 (25.1) <0.001*
ILC 50 12 (24.0) 38 (76.0)
Histologic grade
1 36 19 (52.8) 17 (47.2) 0.297
2 76 51 (67.1) 25 (32.9)
3 125 82 (65.6) 43 (34.4)
Tumor size (cm)
≤2 108 79 (73.1) 29 (26.9) 1.451*
>2 and ≤5 98 60 (61.2) 38 (38.8)
>5 30 13 (43.3) 17 (56.7)
MAI (per 2 mm2)
≤12 103 61 (59.2) 42 (40.8) 0.167
≥13 134 91 (67.9) 43 (32.1)
Lymph node status
Negative 98 65 (66.3) 33 (33.7) 0.544
Positive 125 78 (62.4) 47 (37.6)
* these data have been corrected for the difference in tumor size between
IDC and ILC tumors
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E-cadherin
YAP
Invasive Lobular CarcinomaInvasive Ductal CarcinomaFig. 3 Nuclear YAP expression
is a feature of E-cadherin negative
ILC. E-cadherin status correlates
with nuclear YAP expression.
IDC (left panels) and ILC (right
panels) samples were stained for
E-cadherin (top panels) and YAP
(IHC) (bottom panels). Note the
striking correlation between
nuclear YAP and absence of
E-cadherin expression. Size
bar=50 μm
b
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Fig. 4 Nuclear localization of YAP in human and mouse ILC. Immuno-
fluorescence for E-cadherin (left panels, green) and YAP (YAP-IF,middle
panels, red). Nuclei were visualized using DAPI (blue). Right panels
depict the merged image. In E-cadherin positive human (a) andmouse (b)
cell lines YAP expression is predominantly cytosolic. E-cadherin negative
human (c) and mouse ILC (d) cell lines are characterized by prominent
nuclear YAP expression. Size bar=15 μm
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4 Discussion
This study demonstrates for the first time that nuclear and
cytosol YAP localization are correlated with E-cadherin neg-
ative invasive lobular breast cancer. As YAP is a transcrip-
tional coactivator that shuttles between the cytosol and nucle-
us, we analyzed cytosolic intensity of YAP expression and the
number of YAP positive nuclei. Our results suggest that YAP
does not only translocate into the nucleus of E-cadherin neg-
ative breast cancer, but also that total YAP levels are increased
in this situation. While we have not tested whether YAP
expression levels correlate with YAP activity, it was recently
demonstrated that YAP signaling may also be regulated
through YAP degradation [21]. It is currently unknownwheth-
er E-cadherin expression regulates YAP degradation. A pos-
sibility might be that loss of E-cadherin inhibits YAP phos-
phorylation and subsequent ubiquitin-mediated degradation,
leading to increased levels of YAP. However, while we ob-
served a correlation between membranous E-cadherin expres-
sion and cytoplasmic YAP localization, total YAP protein
levels did not seem to correlate with E-cadherin status in the
human breast cell lines (data not shown). This discrepancy
may reflect differences between cultured cell lines and clinical
breast cancer specimens.
In contrast to previous studies [19, 28], we did not find a
correlation between YAP expression/localization and overall
survival of breast cancer patients. We did not observe a
statistically significant correlation between YAP expression/
localization and overall survival (data not shown). We think
that the lack of correlation in our cohort is not surprising, since
YAP is strongly linked to ILC, and differences in survival
rates for ILC and IDC patients are only observed when
comparing large numbers of patients over long time periods
of more than 10 years [46].
An interesting yet unanswered question is the possible link
between YAP localization/function and E-cadherin negative
IDC. In contrast to early mutational inactivation of E-
cadherin in ILC, IDC tends to show loss of E-cadherin by
epigenetic mechanisms during later stages of tumor progres-
sion [1, 47, 48]. Since almost all our IDC cases showed
membranous expression of E-cadherin (97 %), this prevented
an in-depth survey into the localization of YAP in E-cadherin
negative IDC.
Our current findings are in line with recent data that
addressed a scenario whereby stress fiber formation resulted
in a reduction of YAP phosphorylation and subsequent nucle-
ar localization [17, 20, 22]. Although the impact of cell-cell
adhesion was not directly addressed in these studies, it was
recently shown that E-cadherin-dependent contact inhibition
and a resulting reduction in proliferation may be regulated
through Lats-dependent phosphorylation of YAP [18]. Cell-
type specific differences may play a role, as morphology-
dependent F-actin bundling can also regulate YAP in a Lats-
independent manner [17]. Regardless of the exact mechanism,
a common denominator in the nuclear localization of YAP
seems the activation of Rho-Rock-driven actin polymeriza-
tion. As such, both cellular morphology and cadherin-
mediated cell-cell binding may regulate YAP-mediated tran-
scriptional activity in a tension-dependent manner.
Interestingly, YAP overexpression can also cause transforma-
tion of E-cadherin expressing breast cancer cells, which is
accompanied by loss of epithelial characteristics, expression
of mesenchymal markers and acquisition of invasiveness and
anchorage-independence [22, 24, 49]. Thus, irrespective of
the upstream signaling cascade, nuclear YAP may play a
central role in the regulation of breast cancer invasiveness.
We have previously demonstrated that loss of junctional
integrity through mutational inactivation of E-cadherin leads
to a p120-catenin and MRIP-dependent activation of the Rho-
Rock pathway in metastatic ILC [41]. In this setting, the
functional consequence of active Rock signaling is the regu-
lation of anchorage-independent tumor growth andmetastasis.
Because activation of Rock directs actin polymerization, this
may result in dephosphorylation and subsequent nuclear
membranous expression of E-cadherin and nuclear localiza-
tion of YAP appear to be largely mutually exclusive in mouse
and human breast cancer. We think that actin-dependent nu-
clear translocation of YAP is a plausible mode of action since
several Hippo pathway components bind actin and recent data
indicated that F-actin may regulate YAP downstream of cell
morphology [20, 50–53]. Our recent finding that p120 con-
trols anchorage independence through MRIP-dependent F-
actin bundling [41], may provide an alternative mode of
regulation. Whether p120 links actin polymerization to sub-
sequent nuclear YAP expression in ILC, and how these events
Table 4 Correlation between E-cadherin expression and cytosolic YAP
expression in invasive breast cancer
Feature N Cytosolic YAP expression
Negative N (%) Positive N (%) p-value
E-cadherin
Positive 176 114 (64.8) 62 (35.2) 0.024
Negative 49 23 (46.9) 26 (53.1)
Table 5 Correlation between E-cadherin expression and nuclear YAP
expression in invasive breast cancer
Feature N Nuclear YAP expression
Low (<20 %) N (%) High (≥20 %) N (%) p-value
E-cadherin
Positive 176 127 (72.2) 49 (27.8) <0.001
Negative 50 15 (30.0) 35 (70.0)
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contribute to ILC development and metastasis, is subject of
further research.
To summarize, our results show that nuclear YAP localiza-
tion and overall YAP expression levels significantly correlate
with the ILC breast cancer subtype, a malignancy that is
causally related to mutational inactivation of E-cadherin.
These findings were validated in human and mouse E-
cadherin mutant cell lines, which showed an increase in nu-
clear YAP localization compared to E-cadherin expressing
cell lines. We hypothesize that upon loss of E-cadherin and
subsequent inactivation of the AJ complex, YAP translocates
to the nucleus where it may induce a transcriptional program
favoring ILC tumor development and progression. In conclu-
sion, our data suggest that YAP translocation to the nucleus is
a consequence of early mutational inactivation of E-cadherin
and subsequent p120-mediated activation of Rock-dependent
actin polymerization. As such, YAP and its target genes hold
promise for the development of novel intervention strategies
to better treat metastatic ILC.
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